Ragon, B. K., Odenike, O., Baer, M. R., Stock, W., Borthakur, G., Patel, K., . . . Jain, N. (2019). Oral MEK 1/2 Inhibitor Trametinib in Combination with AKT Inhibitor GSK2141795 in Patients with Acute Myeloid Leukemia with RAS Mutations: A Phase II Study. Clin Lymphoma Myeloma Leuk.
Style de citation ChicagoRagon, Brittany Knick, et al. "Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study." Clin Lymphoma Myeloma Leuk 2019.
Style de citation MLARagon, Brittany Knick, et al. "Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study." Clin Lymphoma Myeloma Leuk 2019.